大葉大學圖書館 |

Resistance to targeted ABC transporters in cancer[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.994061
書名/作者:	Resistance to targeted ABC transporters in cancer/ edited by Thomas Efferth.
其他作者:	Efferth, Thomas.
出版者:	Cham : : Springer International Publishing :, 2015.
面頁冊數:	x, 300 p. : : ill. (some col.), digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Drug resistance in cancer cells.
標題:	Cancer - Chemotherapy.
標題:	Biomedicine.
標題:	Cancer Research.
標題:	Drug Resistance.
標題:	Molecular Medicine.
ISBN:	9783319098012 (electronic bk.)
ISBN:	9783319098005 (paper)
內容註:	Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters.
摘要、提要註:	This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance all of these topics and more is explored in this volume.
電子資源:	http://dx.doi.org/10.1007/978-3-319-09801-2

Resistance to targeted ABC transporters in cancer[electronic resource] /
Resistance to targeted ABC transporters in cancer[electronic resource] /edited by Thomas Efferth. - Cham :Springer International Publishing :2015. - x, 300 p. :ill. (some col.), digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.42196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters.

This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance all of these topics and more is explored in this volume.

ISBN: 9783319098012 (electronic bk.)

Standard No.: 10.1007/978-3-319-09801-2doiSubjects--Topical Terms:

603048
Drug resistance in cancer cells.

LC Class. No.: RC271.C5

Dewey Class. No.: 616.994061

Resistance to targeted ABC transporters in cancer[electronic resource] /
LDR:03560nam a2200325 a 4500 001 424822
003 DE-He213
005 20150609145556.0
006 m d
007 cr nn 008maaau
008 151119s2015 gw s 0 eng d
020 $a 9783319098012 (electronic bk.)
020 $a 9783319098005 (paper)
024 7 $a 10.1007/978-3-319-09801-2 $2 doi
035 $a 978-3-319-09801-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b R433 2015
245 0 0 $a Resistance to targeted ABC transporters in cancer $h [electronic resource] / $c edited by Thomas Efferth.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a x, 300 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.4
505 0 $a Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters.
520 $a This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance all of these topics and more is explored in this volume.
650 0 $a Drug resistance in cancer cells. $3 603048
650 0 $a Cancer $x Chemotherapy. $3 382675
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Drug Resistance. $3 466595
650 2 4 $a Molecular Medicine. $3 463625
700 1 $a Efferth, Thomas. $3 603046
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 603047
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-09801-2
950 $a Biomedical and Life Sciences (Springer-11642)